Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Therapeutics

Histone eviction

Nature Reviews Cancer volume 13, page 441 (2013)Cite this article

Subjects

A paper published in Nature Communications reports that the topoisomerase II inhibitors doxorubicin and daunorubicin induce histone eviction from open chromatin. This effect was independent of the induction of DNA damage by these agents and occurred both in cancer cell lines in vitro and in acute myeloid leukaemia (AML) cells isolated from patients treated with daunorubicin. AML blasts from one patient did not express detectable levels of topoisomerase IIα, leading the authors to suggest that the cytotoxicity of daunorubicin in these cells might result from apoptosis induced by the presence of free histones as a result of histone eviction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Commun. 4, 1908 (2013)

    Article  Google Scholar 

Download references

Authors
  1. Nicola McCarthy
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCarthy, N. Histone eviction. Nat Rev Cancer 13, 441 (2013). https://doi.org/10.1038/nrc3554

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc3554

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing